Chromadex Corp. (CDXC)

4.24
0.09 2.20
NASDAQ : Process Industries
Prev Close 4.15
Open 4.15
Day Low/High 4.09 / 4.30
52 Wk Low/High 2.26 / 7.24
Volume 130.88K
Avg Volume 480.50K
Exchange NASDAQ
Shares Outstanding 46.09M
Market Cap 194.52M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Two Additional Collaborative Human Studies On NIAGEN® With The University Of Cambridge And The University Of Washington Now Registered On Clinical-trials.gov.

Two Additional Collaborative Human Studies On NIAGEN® With The University Of Cambridge And The University Of Washington Now Registered On Clinical-trials.gov.

New Human Clinical Studies Will Investigate the Role of NIAGEN® Nicotinamide Riboside in Mitochondrial Biogenesis and Systolic Heart Failure

ChromaDex Corporation Reports Preliminary 2017 Results   

ChromaDex Corporation Reports Preliminary 2017 Results   

Fourth Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million

National Institutes Of Health (NIH) Announces NIAGEN® Prevents Neurological Damage And Shows Improved Cognitive And Physical Function In A Mouse Model Of Alzheimer's Disease

National Institutes Of Health (NIH) Announces NIAGEN® Prevents Neurological Damage And Shows Improved Cognitive And Physical Function In A Mouse Model Of Alzheimer's Disease

Results of the Collaborative Study Provide Strong Preclinical Support for Nicotinamide Riboside Research in Alzheimer's Patients

Elysium Health, Inc. Challenge Of ChromaDex Licensed Patent Denied By Patent Trial And Appeal Board (PTAB)

Elysium Health, Inc. Challenge Of ChromaDex Licensed Patent Denied By Patent Trial And Appeal Board (PTAB)

ChromaDex's patent portfolio covering its key ingredient in TRU NIAGEN® remains strong

ChromaDex And Watsons Expand Partnership With TRU NIAGEN™ Retail Launch In Singapore

ChromaDex And Watsons Expand Partnership With TRU NIAGEN™ Retail Launch In Singapore

After launching in Hong Kong in September, Watsons expands TRU NIAGEN™ retail distribution to Singapore

Published Study Reveals NIAGEN® Nicotinamide Riboside Is An Effective NAD Precursor To Protect Cardiac Function In An Animal Model Of Heart Failure

Published Study Reveals NIAGEN® Nicotinamide Riboside Is An Effective NAD Precursor To Protect Cardiac Function In An Animal Model Of Heart Failure

New Research Suggests the Protective Benefits of NR May Lead to a New Therapeutic Option in Human Heart Failure

ChromaDex Announces $23 Million Private Placement Of Common Stock

ChromaDex Announces $23 Million Private Placement Of Common Stock

Private Placement Led By High Profile Venture Capitalists and Strategic Investors

ChromaDex To Report Third Quarter 2017 Financial Results On Thursday, November 9, 2017

ChromaDex To Report Third Quarter 2017 Financial Results On Thursday, November 9, 2017

-Company Will Host Investor Conference Call on Thursday, November 9, 2017-

ChromaDex Partners With Asia's Leading Health And Beauty Retailer, Watsons, For TRU NIAGEN™ Retail Launch

ChromaDex Partners With Asia's Leading Health And Beauty Retailer, Watsons, For TRU NIAGEN™ Retail Launch

Hong Kong will be the Initial Market Launch, Soon to be Followed by Additional Asian Locations

ChromaDex® To Report Second Quarter 2017 Financial Results On Thursday, August 10, 2017

ChromaDex® To Report Second Quarter 2017 Financial Results On Thursday, August 10, 2017

Company Will Host Investor Conference Call on Thursday, August 10, 2017

ChromaDex Sponsors Global Gathering Of Scientific Leaders In NAD+ Metabolism And Signaling At The 2017 Federation Of American Societies For Experimental Biology Conference

ChromaDex Sponsors Global Gathering Of Scientific Leaders In NAD+ Metabolism And Signaling At The 2017 Federation Of American Societies For Experimental Biology Conference

Findings from the University of Colorado Boulder Nicotinamide Riboside Human Clinical Trial, to be Presented to the Scientific Community

Short Interest Makes 19.6% Move For CDXC

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 541,781 share increase in total short interest for ChromaDex Corp , to 3,305,741, an increase of 19.60% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

ChromaDex Appoints Harvard Medical School Professor Of Neurology, Dr. Rudolph Tanzi, To The Scientific Advisory Board

Global Alzheimer's Thought Leader to Assist in Exploring Potential for Nicotinamide Riboside in Brain and Neuronal Health

TheStreet Quant Rating: D (Sell)